Patent Application
20180256462
This disclosure relates to fast-acting disinfecting alcohol-based formulations for use on skin.
Hand hygiene is a key fact in the fight against infections associated with care and transmission of pathogenic agent. However, in hospital, compliance of hand cleaning with water and soap is not as important as it should be because there are a lot of constraints (requires hand washing, rinsing and drying followed by hand sanitization); it is the reason why the industry has began to develop some hydro-alcoholic formulations.
Marketed in the 90s, these products were first not appreciated by hygienists who were just promoting compliance of hand washing. Since, quite a few studies have demonstrated that the use of gentle soap, followed by alcohol-based hand sanitizer, reduces the occurrence of occupational hand dermatitis. Today, alcohol-based hand sanitizers are the preferred method for hand hygiene and pre-operatory hand sanitization, in complement of soap.
Alcohol-based hand sanitizers are generally composed of 20-30% of water (which is absolutely necessary for the denaturation of the bacterial proteins), 60-80% of alcohols (ethanol and/or isopropanol and/or n-propanol) and they contain sometimes some extra biocidal agents (i.e. chlorhexidine, quaternary ammoniums, phenolics . . . ) in order to strengthen their initial antimicrobial spectrum of efficacy. These extra biocides may have skin keratolytic and/or irritating properties (some cases of allergy are also described in the specialized literature) when long-term used; therefore, they are not suitable in leave-on products from a purely toxicological point of view.
Without biocidal additives, alcohols have broad-spectrum activity against vegetative gram positive and gram negative bacteria, mycobacteria, yeasts, and enveloped viruses. They are slow-active on fungi (required contact 5 minutes) and they also may be considered as inactive on non-enveloped viruses (also called hydrophilic or naked viruses) within acceptable contact time for the purpose of fast skin hygiene disinfection (1 minute or less). In order to achieve efficacy on naked viruses within one minute or less, some currently marketed hand sanitizers involve 80 to 90% w/w of ethanol and/or n-propanol and/or isopropanol as well as some kill-boosters such as fatty alcohols, surfactants, or glycols. However, increasing the concentration of alcohol to more than 80% may lead to a loss of bactericidal efficacy; 20 to 30% of water being necessary to make the alcohol penetrate into the bacterial cells and coagulate their cytoplasmic proteins. Also, high concentration of alcohol is not suitable in terms of skin tolerance as it increases the trans-epidermal-water-loss and the related skin dehydration. Extra biocidal additives such as quaternary ammoniums, chlorhexidine, triclosan, p-chloro-m-xylenol, iodine, etc, are not suitable either because of the risk of skin irritation and/or sensitization; these additives remaining on the skin all day long and every day for staff working in the medical and the food sectors.
An object of the present disclosure is to provide an alcohol-based composition or formulation, preferably containing from about 60 to about 70% w/w alcohol for use as a hand sanitizer, and having efficacy on most families of pathogenic micro-organisms, including non-enveloped viruses.
Typically, the formulation is free of any co-biocide in addition to the alcohol(s). This reduces the risk of skin irritation or allergy.
In order to improve the in vitro efficacy of the invention on bacteria, yeast and non-enveloped viruses as well as the in vivo efficacy on bacteria, formulation strategy was based on increasing the number of cell-components the ingredients of the composition can target without involving biocidal co-actives. The ultimate composition obtained combines alcohol(s) with ingredients in a synergistic formulation having satisfactory skin compatibility, no or little intrinsic antimicrobial properties and the potential to increase the spectrum of activity as well as the germ kill rate of the formulation due to their chemical action on the microbial cell components.
The present disclosure provides low or high alcohol content compositions, with high level of antimicrobial efficacy, which contain a surfactant/wetting agent as well as a disinfectant/solvent/carrier and that causes very little drying to the skin or the hands of the user and is able to be dispensed as a liquid, as a gel, as a foam or dispensed from a pressurized system.
Accordingly, an aspect of the present disclosure provides a liquid composition for personal hygiene. The composition can be a foaming formulation. The composition can be a thickened formulation.
An aspect of the present disclosure is a skin disinfectant composition or formulation, comprising:
An aspect of the disclosure is a composition formulated as a foaming composition. Such foaming formulations include a surfactant present in an amount of about 1 to 5% w/w of the composition.
Another aspect of the present disclosure is one in which the composition is thickened by a rheology modifier present in amount of from about 0.01 to about 10% w/w of the composition.
In another embodiment there is provided a method of cleansing or santization skin, particularly hands, which comprises applying the composition of the present disclosure to the skin.
Embodiments will hereinafter be described with reference to the accompanying drawings, which have not necessarily been drawn to scale.
In an aspect, the invention provides a fast acting hydro-alcoholic skin disinfecting (bactericidal, fungicidal and virucidal) solution that includes at least one C2 to C5 aliphatic alcohol. The alcohol can be one alcoholic component can be a single alcohol or a mixture of alcohols, especially one or more of ethanol, n-propanol, and/or isopropanol. The concentration of the alcohol(s) component is an amount from about 0.1 to about 90% w/w, of the solution, preferably the alcohol is ethanol at 60 to 70% w/w, and more preferably present at a concentration of about 70% w/w of the composition.
The composition includes at least one chelating agent present in a concentration of from about 0.1 to about 5% w/w. The chelating agent component can be one or more chelating agents chosen from glutamic acid, phosphoric acid, phosphonic acids having 1 to 5 phosphonic acid groups, e.g. 1-hydroxyethylidene-1,1,-diphosphonic acid, amino tri(methylene phosphonic acid), diethylenetriaminepenta(methylene phosphonic acid), 2-hydroxy ethylimino bis(methylene phosphonic acid), and ethylene diamine tetra(methylene phosphonic acid), sodium tripolyphosphate, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), N-(hydroxyethyl)-ethylenediami-netriacetic acid (HEDTA), 2-hydroxyethyliminodiacetic acid (HEIDA), iminodisuccinic acid, polyaspartic acid, tetrasodium glutamate diacetate, and so can be any combination of any of the foregoing. A preferred chelating agent is tetrasodium glutamate diacetate, and preferably the chelating agent(s) component of the composition is present in an amount of about 0.4% w/w.
The composition includes a component that is at least one hydrotrope present in an amount of from about 0.1 to about 5.0% w/w of the composition or formulation. The one or more hydrotrope can be chosen from xylene sulfonic acid, sodium xylene sulfonate, ammonium xylene sulfonate, calcium xylene sulfonate, potassium xylene sulfonate, toluene sulfonic acid, sodium toluene sulfonate, ammonium toluene sulfonate, cumene sulfonic acid, sodium cumene sulfonate, ammonium cumene sulfonate, phosphate polyether ester, alkyldiphenyloxide disulfonate, and any combination of any of the foregoing. A preferred hydrotrope is cumene sulfonic acid or its salt. A preferred amount of the hydrotrope(s) componenent is about 0.5% w/w.
The composition includes at least one acid. The acid(s) can be inorganic and/or organic acids. The acid(s) component is present in an amount ranging from about 0.01 to about 5 wt/wt % of the composition and the one or more acid(s) is selected to adjust the pH of the formulation in a range from about pH 2 to about pH 6. Acid(s) can be selected from alpha-hydroxy-acids (e.g. citric acid, lactic acid, tartric acid, malic acid, glycolic acid), maleic acid, propanoic, butanoic, pentanoic, hexanoic, heptanoic, octanioc mono-, di- and tri-acids, beta-hydroxy-acids, phosphoric acid, and any combination thereof. A preferred acid is phosphoric acid, and preferably the formulation has a pH of about 4.5. The composition includes one or more alkylbenzene sulfonate chosen from those having 10 to 16 carbons present in an amount of from about 0.1 to about 1.0% w/w of the composition. The one or more alkylbenzene sulfonate(s) can be chosen from sodium decylbenzene sulfonate, sodium dodecylbenzene sulfonate, sodium tridecylbenzene sulfonate, and so can be a combination of any of these. A preferred alkylbenzene sulfonate is alkylbenzene sulfonate and a preferred concentration of the alkylbenzene sulfonate(s) is 0.1% w/w.
The composition includes one or more chaotrope(s) present in a concentration of from about 0.01 to about 10% w/w of the composition. A preferred chaotrope is the denaturant urea and a preferred concentration of the chaotrope(s) component is between about 0.1 and about 5% w/w, more preferably about 1% w/w of the composition.
A composition of the present disclosure also includes one or more sesquiterpenoid(s), this component being present as about 0.01 to about 1% w/w of the composition. In an embodiment, the at least one sesquiterpenoid is chosen from nerolidol, farnesol, bisabolol, and apritone, and can be a combination of any of these. A preferred concentration of the sesquiterpenoid(s) component is about 0.1% w/w of the composition.
The composition also includes at least one skin moisturizing and/or conditioning and/or emollient agent in a concentration of from about 0.01 to about 10% w/w of the formulation. Such ingredients can be chosen from polyols and glycols such as glycerol, polyglycerol, sorbitol, mannitol, erythritol, xylitol, arabitol, ribitol, dulcitol, lactitol, maltitol, propylene glycol, polyethylene glycol, hexylene glycol, butylene glycol, allantoin, phospholipids such as soya lecithin, ceramides, essential fatty acids such as linolenic acid, gamma-linolenic acid, linoleic acid, and gamma-linoleic acid, vitamins such as d-panthenol and tocopherols, cationics such as quaternised gums quaternised guar gum, dihydroxypropyl PEG-5 linoleammonium chloride, behentrimonium chloride, and polyquaterniums, sugar derivatives such as glucose-ethers such as methyl gluceth-20, glycerol esters such as glyceryl oleate, glyceryl palmate, glyceryl cocoate, and glyceryl undecylenate, and vegetable extracts such as Matricaria chamomilla, Aloe vera, and Glycyrrhiza glabra L. A prefered moisturizer is d-panthenol, and a preferred concentration is in the range of from about 0.01 to 1% w/w of the composition. A preferred concentration of the one or more at skin moisturizing and/or conditioning and/or emollient agent is about 0.5% w/w of the composition.
As mentioned previously, water is present in an amount to balance the total composition to 100% w/w.
A composition of the invention can also be prepared as foam that contains at least one surfactant. For such foaming versions, the one or more surfactant(s) can be chosen from ethoxylated dimethicone having a “comb structure” i.e., having a functional group located at an internal position of the molecule, or a “terminal structure” in which the functional group is located at the ends of the molecule. Examples are 3-(3-Hydroxypropyl)-heptamethyltrisiloxane, polyether-modified polysiloxane or a polysiloxane betaine, alkenyl esters or diesters of sulfosuccinic acid in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms, and an alkali metal, triethanolamine, sodium, ammonium, calcium or magnesium, C8 to C18 alkyl ether sulfates, or C8-C18 alkyl amine oxide, or alkylpolyglusoside, or water-soluble resin such as non-ionic polymers of ethylene oxide with molecular weight ranging from 100,000 to 4000,000 Daltons. A preferred surfactant is Bis-PEG-12 dimethicone at 1 to 5% w/w of the composition, and a preferred concentration is about 1.00% w/w. A preferred water-soluble resin is polyethylene oxide with a molecular weight of 1000,000 at a preferred concentration of 0.05% w/w of the composition.
A composition of the invention can be thickened, containing at least one rheology modifier at a concentration of from about 0.01 to about 10% w/w of the composition. The one or more rheology modifier can be chosen from acrylates/C10-30 alkyl acrylate crosspolymer, carbomer, xanthan gum, guar gum, cellulose ether, quaternised guar gum, alginate and bentonite, and combination thereof. A preferred range is from about 0.1 to about 10% w/w of the composition. A preferred thickener is acrylates/C10-30 alkyl acrylate crosspolymer or carbomer at 0.1 and 1% w/w of the gel formulation.
Preferred additives are described in greater detail below.
Cumene sulfonic acid, also known as benzenesulfonic acid, (1-methylethyl) cumene sulfonic acid (CAS: 16066-35-6), is a hydrotrope; as such it should help to solubilise hydrophobic membranes and envelopes of micro-organisms. Therefore, in the present invention, cumene sulfonic acid is believed to improve the bactericidal and yeasticidal properties of the involved alcohol(s).
Tetrasodium glutamate diacetate, also known as tetrasodium N,N-bis(carboxylatomethyl)-L-glutamate (CAS: 51981-21-6), is a biodegradable and safe as a cosmetic chelating agent. It is a substitute for EDTA.
Bacteria require metal ions to satisfy the specific requirements of metal-enzyme and cell-wall structural components. Chelators are able to increase the permeability of the bacterial cell wall by sequestering the necessary metals (Fe2+ in particular). They also can capture the metal ions (Mg2+ in particular) acting as cofactors for the DNA synthesis and involved in the LipoPolySaccharide's cohesion.
In the present invention, tetrasodium glutamate diacetate is believed to improve the killing rate on gram negative bacteria mainly.
A natural sesquiterpene, also called peruviol or 3,7,11-trimethyl-1,6,10-dodecatrien-3-ol (CAS: 7212-44-4), nerolidol is found in the essential oils of many types of plants and flowers, and with potential bactericidal and fungicidal properties.
The antimicrobial activity of nerolidol has been documented in various studies. A study (1) consisting of evaluating the antibacterial effects of three terpene-alcohols (farnesol, nerolidol and plaunotol) on Staphylococcus aureus, focusing on the leakage of K+ ions and toxicity over time, suggested that the terpene alcohols might act on cell membranes. The antibacterial activity reflected the initial rate of leakage of K+ ions, suggesting that damage to cell membranes might be one of the major modes of action of these terpene alcohols. The results also demonstrated that the initial rate of leakage and the amount of leaked K+ ions are useful as indices of the antibacterial activities of hydrophobic compounds.
In another study (2), sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone were investigated for their abilities to enhance bacterial permeability and susceptibility to exogenous antimicrobial compounds. Initially, it was observed by flow cytometry that these sesquiterpenoids promoted the intracellular accumulation of the membrane-impermeant nucleic acid stain ethidium bromide by live cells of Lactobacillus fermentum, suggesting that enhanced permeability resulted from disruption of the cytoplasmic membrane. In disk diffusion assays, treatment with low concentrations (0.5 to 2 mM) of nerolidol, bisabolol, or apritone enhanced the susceptibility of Staphylococcus aureus to ciprofloxacin, clindamycin, erythromycin, gentamicin, tetracycline, and vancomycin. Nerolidol and farnesol also sensitized Escherichia coli to polymyxin B.
A more recent study (3) allowed elucidating the antifungal activities of eugenol and nerolidol isolated from Japanese cypress oil in a guinea pig model infected by Microsporum gypseum. A minimal inhibitory concentration (MIC), skin lesion scoring, hair culture and histopathologic examination of skin tissues were performed to evaluate the antifungal effect of these oils. The MICs of eugenol, nerolidol and econazole (positive control) were 0.01-0.03% and 0.5-2% and 4-16 μg/ml, respectively. Based on these MICs, eugenol and nerolidol were adjusted to 10% concentration with a base of Vaseline® petroleum jelly and were applied topically to the skin lesion infected with M. gypseum daily for 3 weeks. Both eugenol and nerolidol were clinically effective at improving the lesion during the first week of application, as determined by skin lesion scoring. Nerolidol improved the skin lesions infected by M. gypseum, but eugenol did not, as determined in the hair culture test. Histopathologic examination revealed that the eugenol- and nerolidol-treated groups had a lower degree of hyperkeratosis and inflammatory cell infiltration than the positive control. Taken together, these results suggest that eugenol and nerolidol could apply supplementary antifungal agents.
In the present disclosure, nerolidol is believed to improve the killing rate on gram negative bacteria.
Urea, also known as carbamide, carbonyl diamide, carbonyldiamine, diaminomethanal, or diaminomethanone (CAS: 57-13-6), is a powerful chaotrope used for denaturing proteins; it has the potential to disrupt the non-covalent bonds of secondary and tertiary structures of cellular proteins and enzymes of bacteria, fungi and viruses; denatured proteins will unfold into long polypeptide chains without involving the hydrolysis or destruction of the peptide bonds.
In the present disclosure, urea is believed to improve the killing rate on gram negative bacteria, yeasts, and non-enveloped viruses.
Dodecylbenzene sulfonic acid is also known as Alky-aryl-sulfonic acid; Alky-benzene-sulfonic acid; 4-dodecyl-benzene sulfonic acid; p-dodecyl-benzene sulfonic acid (CAS: 121-65-3). The choice of such an anionic compound is based on theoretical approach: most aminoacids composing the proteins of viral capsids have their isoelectric points at around 5-6, therefore, at acidic pH these amino acids become cationic. At pH<5 and in the presence of anionic compounds the aminoacids should precipitate because they have reached the point of minimum water solubility.
Anionic surfactants should also disrupt the intramolecular ionic bonds of proteins and solubilise bacterial, fungal and viral lipid membranes or envelop.
In the present disclosure, dodecyl benzene sulfonic acid is believed to improve the killing rate on gram negative bacteria, yeasts, and enveloped as well as non-enveloped viruses.
Except where explicitly indicated, all numbers in this description indicating amounts or ratios of materials, conditions of reaction; physical properties of materials and/or use; dimensions and dimension ratios, are to be understood as modified by the word “about”.
The term “comprising” is meant not to be limiting to any subsequently stated elements but rather to encompass non-specified elements of major or minor functional importance. In other words the listed steps, elements or options need not be exhaustive. Whenever the words “including” or “having” are used, these terms are meant to be equivalent to “comprising” as defined above. It should be noted that in specifying any range of concentration or amount, any particular upper concentration or amount can be associated with any particular lower concentration or amount. Reported ranges are inclusive of their endpoints.
All parts, percentages, ratios, and proportions referred to in this specification, including the claims, are by weight unless otherwise indicated.
The following Examples will more fully illustrate the embodiments of this disclosure. The examples are not intended to limit the scope of the invention in any manner.
All above formulations were subject to preliminary in vitro and in vivo testing in order to pre-evaluate their level of microbiocidal efficacy on gram positive and gram negative bacteria, as well as yeast and non-enveloped virus.
All formulations were tested against one reference 70% w/w ethanol aqueous solution and one market alcohol-based hand sanitizer containing ethanol 65% w/w and n-propanol 10% w/w.
In vitro bactericidal tests: ASTM E2315-03 time-kill test on Escherichia coli ATCC 11229 and Staphylococcus aureus ATCC 6538, with a contact time of 15 seconds and a concentration in product of 80% vol/vol. See
In vitro yeasticidal tests: EN13624 norm on Candida albicans ATCC 10231, with a contact time of 15 seconds and a concentration in product of 80% vol/vol. See
In vitro virucidal tests: EN14476 norm on Poliovirus, with a contact time of 30 seconds and a concentration in product of 80% vol/vol. See
For in vivo bactericidal tests: EN1500 norm on Escherichia coli K12, involving 5 subjects, a contact time of 30 seconds and a volume of product of 3 ml. See
For all of the above tests, the test-formulations were more effective on bacteria (Escherichia coli and Staphylococcus aureus), the yeast (Candida albicans) and the non-enveloped virus (Poliovirus) than the reference 70° ethanol solution and the reference market hand sanitiser. This supports the proposition that the additives have increased the microbiocidal properties of the alcohol (ethanol at 70% w/w).
Prior to performing in vivo or in vitro skin irritation tests, skin irritation scores were calculated in accordance with the Directive 1999/45/EC (‘Classification, Packaging and Labelling of Dangerous Preparations’) of the European Parliament and of the Council of 31 May 1999.
According to the directive, none of the above formulations is classified as «irritating to skin» (the limit being ‘1’) and because the calculated scores are very low (all <0.1), they may be considered as very mild to the skin.
An in vivo study of acute skin compatibility has also been conducted on 11 subjects and using the 48-hours a semi-occlusive patch-test method. The most concentrated formulation (#8) was tested pure and was classified as “non-irrating to the skin” as the obtained mean irritation index (M.I.I.) was zero.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/GB2016/052782 | 9/8/2016 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62234933 | Sep 2015 | US |
